Current Trials

IF YOU, OR SOMEONE YOU KNOW, IS OVER 18 YEARS OF AGE AND ARE INTERESTED IN ANY OF OUR CURRENT CLINICAL TRIALS LISTED, PLEASE CONTACT RESEARCH AT ASHEVILLE GASTROENTEROLOGY FOR MORE INFORMATION TO SEE IF YOU MIGHT QUALIFY. IF ELIGIBLE, MOST TRIALS WILL COVER THE COST OF TRIAL-RELATED EXPENSES AND/OR STIPEND. PLEASE PROVIDE YOUR CONTACT INFORMATION WITH YOUR E-MAIL TO RESEARCH@ASHEVILLEGASTRO.COM AND A STUDY COORDINATOR WILL CONTACT YOU!

Ulcerative Colitis

1) Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis (Receptos/Celgene).

Read More

2) A Long-Term Registry of Humira® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)-LEGACY-(ABBVIE)

Read More

3) Qualitative Interviews with Patients Diagnosed With Ulcerative Colitis Undergoing Colonoscopy. #2283A (Robarts)

Crohn’s Disease

1) Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients with CD Receiving Anti-TNF Therapy (PIONEER-CD)-(Nestle/Robarts)

Read More

2) Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn’s Disease (Celgene) (GED-CD-001)

Read More

3) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn’s Disease (GED-CD-003)-Celgene

Read More

4) A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn’s Disease (GED-CD-004)-Celgene

Read More

6) BI 695501 versus Humira® in patients with active Crohn’s disease: a randomized, double-blind, multicenter, parallel group, non-inferiority trial comparing efficacy, endoscopic improvement, safety, and immunogenicity (Boehringer-Ingelheim)

Read More

6) Qualitative Interviews with Patients Diagnosed With Crohn’s Disease Undergoing Colonoscopy: #2122A (Robarts)

Non-alcoholic Fatty Liver Disease (NASH)

1) Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE)-(Intercept Pharmaceuticals)

Read More 

2) A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis-(Intercept Pharmaceuticals)

3) A Multicentre Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Non-Alcoholic Steatohepatitis (NASH) and fibrosis-RESOLVE-IT (GenFit)

Read More

Hepatitis-C

1) HCV-TARGET-Observational Hepatitis C Therapeutic Registry and Research Network (UF-UNCCH)

Read More

Colonoscopy/Bowel Prep

1) A Randomized, Investigator-Blinded, Non-Inferiority, Multicenter Study Evaluating the Safety and Efficacy of DCL-101 Compared to GoLytely in Adult Outpatients Undergoing Routine Colonoscopy (Dark Canyon Labs)

Read More 

2) Multicenter, Prospective, Randomized Study Comparing the Diagnostic Yield of Colon Capsule Endoscopy Versus Computed Tomographic Colonography in a Screening Population (Medtronics)

Read More

3) A Safety and Efficacy Comparison of BLI4700 Bowel Preparation versus an FDA-approved Comparator in Adult Subjects prior to Colonoscopy (Braintree)

Eosinophilic Esophagitis (EOE)

1) Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study (SHIRE)

Read More

H-PYLORI

1) Helicobacter pylori Sample Collection Protocol PRE-THERAPY Subjects (PRE-TREAT A001)-DIASORIN

Read More 

Fecal Calprotectin

1) CALFE Stool Sample Collection Protocol-DIASORIN

Read More

Please Note: We maintain an ongoing list of eligible candidates for many GI and liver diseases, so if we do not currently have an open and enrolling trial listed, you may request we keep your name in our referral database for future GI-related trials as they become available.